In exchange, uniQure granted Benitec a non-exclusive access to its AAV5 delivery technology for the development of a ddRNAi therapy for Hepatitis B.
Benitec’s ddRNAi technology has the ability to silence the gene responsible for producing the mutant protein that is responsible for Huntington’s disease, claims uniQure.
Benitec Biopharma CEO Peter French said the uniQure has received market approval for a gene therapy product, Glybera, in the West, thus the company is pleased to execute the licensing agreement.
"uniQure have demonstrated their unique ability to take gene therapy-based programs from pre-clinical stages to commercialization, and we are confident that they will be able to achieve a similar outcome in this program," French added.